SYGNOMICS aims to help clinicians improve patient outcomes at scale by accurately applying systems biology to cancer care.
SYGNOMICS is developing an end-to-end solution that uses a unique and disruptive approach to enable personalized precision medicine for cancer patients. This solution will be powered by the Systems Genetics Network AnaLysis (SYGNAL) technology, which can accurately risk stratify a patient and personalize therapies (drugs and drug combinations) based on the unique characteristics of transcriptional “programs” underlying their disease.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Seattle, Washington, Us
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- http://sygnomics.net
- Keywords
- AI/ML, Healthcare, Risk prediction, Therapy Matching, Computational Biology, Glioblastoma, Multiple Myeloma, Cancer, Precision Oncology, Predictive Modeling, Clinical Decision Support System.
- HQ
- Seattle, Washington
Sygnomics Questions
Sygnomics's website is http://sygnomics.net
Sygnomics's LinkedIn profile is https://www.linkedin.com/company/sygnomics
Sygnomics has
8 employees.
View email and phone details for 8
employees at Sygnomics.
Sygnomics's industry is
Hospitals and Health Care
Sygnomics's top competitors are
Idenxt,
Mckinsey & Company,
N-Power Medicine, Inc.,
Neuralfabric Corp.,
Atomic47 Labs,
Sensassure,
Institute For Systems Biology (Isb),
Syapse,
Hexion Data Storage,
Mast Cell Research Institute.
Sygnomics's categories are Hospitals and Health Care
Sygnomics's founding year is 2020
